title: [Primary nephrotic syndrome treated with urokinase--a report of 20 cases].
abstract: Twenty cases of primary nephrotic syndrome were treated with urokinase at a dosage of 60,000 units per day for two successive weeks. The results showed that after treatment the concentrations of fibrinogen, urine FDP, alpha 2-plasma inhibitor and plasminogen were significantly decreased (P value less than 0.01, less than 0.01, less than 0.001, less than 0.005 respectively). The concentration of antithrombin III was significantly increased (P less than 0.05). It is suggested that the treatment obviously increased the fibrinolytic activity and improved the hypercoagulated state. The clinical data showed that in addition to decrease of proteinuria and obvious increase of urine volume, the clinical manifestations and laboratory parameters showed no significant difference. Further study on the dosage and indications of urokinase is needed and the activity of coagulation and fibrinolysis in patients with deep vein thrombosis of lower extremities was also discussed.
authors.forename: L S
authors.initials: LS
authors.lastname: Wang
authors.forename: E H
authors.initials: EH
authors.lastname: Chen
authors.forename: X J
authors.initials: XJ
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D000990:Antithrombin III / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy*; D010958:Plasminogen / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D000979:alpha-2-Antiplasmin / Q000378:metabolism
chemical_list: D000979:alpha-2-Antiplasmin; D000990:Antithrombin III; D010958:Plasminogen; D014568:Urokinase-Type Plasminogen Activator